Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Conditions

Arthritis, Rheumatoid 10Psoriasis 6Leukemia 5Lymphoma, Follicular 4Myelodysplastic Syndromes 3Inflammation 3Asthma 3Arthritis, Juvenile 3Vasculitis 2Uveitis 2Respiratory Distress Syndrome 2Recurrence 2Prostatic Neoplasms 2Pneumonia 2Neuroblastoma 2Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Granulomatosis with Polyangiitis 2Bronchiolitis Obliterans 2Wilms Tumor 1Temporomandibular Joint Disorders 1Stomatitis 1Spondylitis, Ankylosing 1Spondylarthritis 1Pruritus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plaque, Amyloid 1

Interventions

Etanercept 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Bronchiolitis Obliterans × Etanercept × Clear all
NCT00141726 2015-12-03

Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

University of Michigan Rogel Cancer Center

Phase 2 Completed
34 enrolled 13 charts

Bronchiolitis Obliterans, Respiratory Distress Syndrome, Lung Injury, Acute Lung Injury

NCT00029328 2015-03-25

Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation

FDA Office of Orphan Products Development

Phase 1/2 Completed
15 enrolled

Bronchiolitis Obliterans, Pneumonia, Respiratory Distress Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡